EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis

Shejil Kumar, Matti L Gild, Michelle M McDonald, Albert S Kim, Roderick J Clifton-Bligh, Christian M Girgis

Osteoporosis International · 2024

DOI: 10.1007/s00198-024-07139-9 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Osteoporosis International, 2024. Verfasst von Shejil Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bone Density, Bone Density Conservation Agents, Denosumab. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Sydney.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBone DensityBone Density Conservation AgentsDenosumabDrug Administration ScheduleOsteoporosisOsteoporotic FracturesHumansBone RemodelingDrug Therapy, CombinationLumbar Vertebrae

Stichwörter der Autor:innen

DenosumabOsteoporosisReboundRomosozumabSequence

Substanzen

Antibodies, MonoclonalBone Density Conservation AgentsDenosumabromosozumab

Autor:innen und Institutionen

  • Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia.
  • Faculty of Medicine & Health, University of Sydney, Sydney, Australia.
  • Department of Diabetes & Endocrinology, Royal North Shore Hospital, Sydney, Australia.
  • Faculty of Medicine, University of New South Wales, Sydney, Australia.
  • Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia.
  • Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia. Christian.girgis@sydney.edu.au.

Förderung

  • University of Sydney

Zitieren

APA

Kumar, S., Gild, M. L., McDonald, M. M., Kim, A. S., Clifton-Bligh, R. J., & Girgis, C. M. (2024). A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporosis International. https://doi.org/10.1007/s00198-024-07139-9

Vancouver

Kumar S, Gild ML, McDonald MM, Kim AS, Clifton-Bligh RJ, Girgis CM. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporosis International. 2024. doi:10.1007/s00198-024-07139-9

BibTeX
@article{Kumar2024,
  author = {Kumar, Shejil and Gild, Matti L and McDonald, Michelle M and Kim, Albert S and Clifton-Bligh, Roderick J and Girgis, Christian M},
  title = {A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis},
  journal = {Osteoporosis International},
  year = {2024},
  doi = {10.1007/s00198-024-07139-9}
}
Kostenlos starten →